Loading... Please wait...
Sort by:
  • Payer Insights: RA : Update Bulletin [August 2017]
    Learn More Payer Insights: RA : Update Bulletin [August 2017]
    This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent approvals for biosimilar rituximab products in Europe Celltrion/Mundipharma’s Truxima...
  • Melanoma: KOL Insight: Update Bulletin [August 2017]
    Learn More Melanoma: KOL Insight: Update Bulletin [August 2017]
    This edition presents key opinion leader (KOL) views on recent developments in the malignant melanoma (MM) market. Topics covered include: Array BioPharma submission of two New Drug Applications (NDAs) to the US Food and...
  • HNSCC: Update Bulletin [August 2017]
    Learn More HNSCC: Update Bulletin [August 2017]
    Gain new KOL insights on the latest events happening in head and neck squamous cell carcinoma (HNSCC): data from the Phase I/II ECHO-202/KEYNOTE-037 study of Incyte’s IDO1 inhibitor epacadostat in combination with...
  • Breast Cancer: Update Bulletin [August 2017]
    Learn More Breast Cancer: Update Bulletin [August 2017]
    Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: Roche announcing results from the Phase III APHINITY...
  • NASH: Update Bulletin [August 2017]
    Learn More NASH: Update Bulletin [August 2017]
    Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of nonalcoholic steatohepatitis (NASH). Topics covered include expert opinions on the recent...
  • Payer Attitudes to Orphan Drug Pricing
    Learn More Payer Attitudes to Orphan Drug Pricing
    Payer Attitudes to Orphan Drug Funding The explosion of orphan drugs across Europe and the US is pushing healthcare finances towards breaking point according to payers. Requests for orphan drug designation have reached...
  • Multiple Sclerosis: Update Bulletin [August 2017]
    Learn More Multiple Sclerosis: Update Bulletin [August 2017]
    This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the multiple sclerosis (MS) treatment landscape. Topics covered include; Roche...
  • Acute Myeloid Leukaemia: Update Bulletin [August 2017]
    Learn More Acute Myeloid Leukaemia: Update Bulletin [August 2017]
    This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) space. Topics covered include expert opinions on; Seattle Genetics reporting the...
  • Cystic Fibrosis: Update Bulletin [August 2017]
    Learn More Cystic Fibrosis: Update Bulletin [August 2017]
    This update bulletin edition presents US and EU key opinion leader (KOL) views on recent developments in the cystic fibrosis (CF) space. Topics covered include; Anthera Pharmaceuticals announcing that it has commenced...
  • Adherence – What Do Pharma Really Know
    Learn More Adherence – What Do Pharma Really Know
    Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity but are the right steps being taken to address the most fundamental patient issue: non-adherence? Is ‘big...
  • CAR-T Therapy in Haematological Malignancy: Update Bulletin [July 2017]
    Learn More CAR-T Therapy in Haematological Malignancy: Update Bulletin [July 2017]
    This edition presents US and EU key opinion leader (KOL) views on recent developments in the CAR-T therapy space. Topics covered include expert opinions on Novartis receiving a positive recommendation from the...
  • Prostate Cancer: Update Bulletin [July 2017]
    Learn More Prostate Cancer: Update Bulletin [July 2017]
    Gain new key opinion leader (KOL) insights on the latest events happening in prostate cancer. Topics covered include expert opinions on; the results of the Phase III LATITUDE and STAMPEDE trials investigating...
  • COPD: Update Bulletin [July 2017]
    Learn More COPD: Update Bulletin [July 2017]
    Gain new key opinion leader (KOL) insights on the latest events happening in COPD. Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate), delivered via PARI's investigational eFlow...
  • Ovarian Cancer: Update Bulletin [July 2017]
    Learn More Ovarian Cancer: Update Bulletin [July 2017]
    This update bulletin presents key opinion leader (KOL) insights on recent events in the ovarian cancer treatment landscape. Topics covered include; the US approval and launch of Tesaro's PARP inhibitor Zejula (niraparib)...
  • Targeted Therapies in Asthma: Update Bulletin [July 2017]
    Learn More Targeted Therapies in Asthma: Update Bulletin [July 2017]
    This edition presents the views and insights from three key opinion leaders (KOLs) from the US and Europe on a variety of recent events in the severe asthma treatment landscape. Topics covered include; Novartis...
  •  Market Access Impact: Multiple Sclerosis (EU5) 2017
    Learn More Market Access Impact: Multiple Sclerosis (EU5) 2017
    Market barriers affect nearly 15% of multiple sclerosis prescriptions in the EU5 In the EU5 countries, market barriers affect a modest 15% of multiple sclerosis prescriptions, but they’re giving market share to...

customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved